Cardiovascular event risk reduction in type 2 diabetes mellitus

Cardiovascular event risk reduction in type 2 diabetes mellitus is a preventative clinical objective aimed at decreasing the incidence of major adverse cardiovascular events—such as myocardial infarction, stroke, and cardiovascular death—in individuals with type 2 diabetes

Cardiovascular event risk reduction in type 2 diabetes mellitus is a preventative clinical objective aimed at decreasing the incidence of major adverse cardiovascular events—such as myocardial infarction, stroke, and cardiovascular death—in individuals with type 2 diabetes

This metabolic disorder extensively impacts the cardiovascular and vascular systems through chronic hyperglycemia, tissue insulin resistance, systemic inflammation, and dyslipidemia These interconnected processes accelerate atherogenesis, promote endothelial dysfunction, and induce vascular remodeling, which markedly elevates the risk for occlusive macrovascular complications and heart failure

This metabolic disorder extensively impacts the cardiovascular and vascular systems through chronic hyperglycemia, tissue insulin resistance, systemic inflammation, and dyslipidemia These interconnected processes accelerate atherogenesis, promote endothelial dysfunction, and induce vascular remodeling, which markedly elevates the risk for occlusive macrovascular complications and heart failure

Consequently, therapeutics targeting this indication are indicated to mitigate these heightened macrovascular risks, particularly in patients with established atherosclerotic cardiovascular disease or multiple cardiometabolic risk factors

Consequently, therapeutics targeting this indication are indicated to mitigate these heightened macrovascular risks, particularly in patients with established atherosclerotic cardiovascular disease or multiple cardiometabolic risk factors